Prosecution Insights
Last updated: October 04, 2026
Application No. 18/617,246

DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS

Non-Final OA §112
Filed
Mar 26, 2024
Priority
Jul 02, 2018 — provisional 62/692,858 +4 more
Examiner
HAGOPIAN, CASEY SHEA
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Incept LLC
OA Round
3 (Non-Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
9m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
310 granted / 570 resolved
-5.6% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
42 currently pending
Career history
617
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
42.4%
+2.4% vs TC avg
§102
12.1%
-27.9% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 570 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/15/2026 has been entered. Status of the Claims No claims were amended or newly added. Claims 1-15 and 21 were previously cancelled. Accordingly, claims 16-20 remain pending in the application. Drawings The drawings were received on 5/6/2026. These drawings are acceptable. Information Disclosure Statement The IDS dated 6/15/2026 has been considered. A signed copy is enclosed herewith. Claim Objections Claims 16 and 20 are objected to because of the following informalities: the claims recite, “a distal end wall located opposite a proximal end wall, the concave wall extends between the distal end and the proximal end” in lines 8-9 of claim16 and lines 10-11 of claim 20. The phrases, “the distal end” and “the proximal end” do not have proper antecedent basis, but do not rise to the level of indefiniteness. For improved clarity, it is suggested that “a distal end wall located opposite a proximal end wall, the concave wall extends between the distal end and the proximal end” is replaced with “a distal end wall located opposite a proximal end wall, the concave wall extends between the distal end wall and the proximal end wall”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 19 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 19 recites, “wherein the form further comprises at least one stabilizing feature being confirmed to stabilize the form”. Claim 19 depends from claim 16. Claim 16 sets out the same limitation at lines 12-13 of the claim. Accordingly, claim 19 does not properly further limit the subject matter of claim 16. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: The prior art does not teach or reasonably suggest a form for creating an in situ nerve cap to inhibit neuroma formation, the form comprising: a concave wall at least partially defining a cavity, the concave wall comprising a top opening for accessing the cavity, the top opening lying on a first plane and having an area less than an area of a second plane, the second plane conforming to inside dimensions of the cavity, the second plane being spaced apart from the first plane within the cavity and being parallel to the first plane; a distal end wall located opposite a proximal end wall, the concave wall extends between the distal end (wall) and the proximal end (wall); and a concave nerve guide located at the proximal end wall providing a side access to the cavity; wherein the form further comprises at least one stabilizing feature being configured to stabilize the form, and wherein the at least one stabilizing feature comprises a transverse support surface extending along or parallel to a tangent to the concave wall; or a kit thereof. The closest prior art is Phillips in view of Mueller (of record). See Office Actions dated 6/18/2025 and 1/27/2026 for details. The prior art does not teach or reasonably suggest the limitation, “wherein the at least one stabilizing feature comprises a transverse support surface extending along or parallel to a tangent to the concave wall”. See, e.g., stabilizing feature 32 of Fig. 3 of the instant application. Thus, the prior art cannot teach or reasonably suggest the claimed invention. Conclusion Claims 16 and 20 are objected to; claim 19 is rejected; and claims 17 and 18 allowable. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CASEY HAGOPIAN whose telephone number is (571)272-6097. The examiner can normally be reached on M-F 9:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached on 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Casey Hagopian Examiner, Art Unit 1617 /CARLOS A AZPURU/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Mar 26, 2024
Application Filed
Jun 18, 2025
Non-Final Rejection mailed — §112
Sep 18, 2025
Response Filed
Jan 27, 2026
Final Rejection mailed — §112
Mar 13, 2026
Response after Non-Final Action
Jun 15, 2026
Request for Continued Examination
Jun 17, 2026
Response after Non-Final Action
Sep 17, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12708698
Formulation comprising a phosphocalcic cement and a physical and/or covalent hydrogel of polysaccharides, printable and having ductile mechanical properties for bone regeneration/bone repair
3y 10m to grant Granted Aug 18, 2026
Patent 12691079
A BIODISSOLVABLE FILM FOR LOCALIZED AND EFFICIENT TREATMENT OF VULVODYNIA
4y 3m to grant Granted Jul 28, 2026
Patent 12673139
3D PRINTED UV CROSSLINKING MASKS
3y 10m to grant Granted Jul 07, 2026
Patent 12661430
PARTICLE SUITABLE FOR THE MANUFACTURE OF AN IMPLANTABLE SOFT TISSUE ENGINEERING MATERIAL
3y 6m to grant Granted Jun 23, 2026
Patent 12653785
COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION
2y 11m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
88%
With Interview (+33.3%)
3y 4m (~9m remaining)
Median Time to Grant
High
PTA Risk
Based on 570 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month